An Open-label Safety and Efficacy Study of VY-AADC01 Administered by MRI-Guided Convective Infusion Using a Posterior Trajectory Into the Putamen of Participants With Parkinson's Disease With Fluctuating Responses to Levodopa
Phase of Trial: Phase I
Latest Information Update: 03 Oct 2017
At a glance
- Drugs AAV-hAADC (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions
- Sponsors Voyager Therapeutics
- 06 Sep 2017 According to a Voyager Therapeutics media release, the company plans to report updated results from this trial during the first quarter of 2018.
- 06 Sep 2017 According to a Voyager Therapeutics media release, the company completed dosing additional patients in this trial.
- 06 Sep 2017 Results published in the Voyager Therapeutics Media Release